Zacks Research Issues Positive Estimate for ResMed Earnings

ResMed Inc. (NYSE:RMD) – Analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of ResMed in a research report issued to clients and investors on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.25 per share for the quarter, up from their prior forecast of $2.13. The consensus estimate for ResMed’s current full-year earnings is $9.28 per share. Zacks Research also issued estimates for ResMed’s Q1 2027 earnings at $2.44 EPS.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.17. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period last year, the company earned $1.64 earnings per share.

RMD has been the topic of a number of other research reports. Royal Bank of Canada increased their price target on shares of ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a report on Friday, October 25th. Wolfe Research reissued an “underperform” rating and issued a $180.00 target price on shares of ResMed in a report on Wednesday, September 18th. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Bank of America lifted their price objective on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, September 26th. Finally, KeyCorp upped their target price on shares of ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, ResMed currently has a consensus rating of “Moderate Buy” and an average price target of $225.70.

ResMed Stock Performance

Shares of RMD stock opened at $234.77 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. The company has a market capitalization of $34.46 billion, a price-to-earnings ratio of 30.99, a price-to-earnings-growth ratio of 1.71 and a beta of 0.69. ResMed has a one year low of $147.39 and a one year high of $260.49. The company’s 50-day moving average is $243.03 and its 200 day moving average is $223.42.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Thursday, November 7th. ResMed’s payout ratio is 28.08%.

Insider Buying and Selling at ResMed

In related news, insider Kaushik Ghoshal sold 5,000 shares of ResMed stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the transaction, the insider now directly owns 21,788 shares in the company, valued at approximately $5,502,777.28. The trade was a 18.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Michael J. Rider sold 882 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total value of $203,742.00. Following the completion of the sale, the general counsel now owns 10,512 shares of the company’s stock, valued at approximately $2,428,272. The trade was a 7.74 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,056 shares of company stock valued at $15,086,020. Insiders own 0.71% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RMD. UMB Bank n.a. raised its stake in ResMed by 1.9% during the 3rd quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock worth $602,000 after acquiring an additional 47 shares during the period. Ascent Group LLC increased its stake in shares of ResMed by 1.7% in the third quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider’s stock worth $714,000 after purchasing an additional 48 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its position in shares of ResMed by 3.7% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 1,473 shares of the medical equipment provider’s stock valued at $292,000 after purchasing an additional 52 shares during the period. QRG Capital Management Inc. lifted its stake in shares of ResMed by 4.5% during the 2nd quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock valued at $247,000 after buying an additional 56 shares in the last quarter. Finally, Inspire Advisors LLC boosted its holdings in ResMed by 1.9% in the 2nd quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock worth $586,000 after buying an additional 56 shares during the period. 54.98% of the stock is owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.